In acute myeloid leukemia (AML), leukemia-initiating cells exist within the CD341/CD382 cell compartment. They are assumed to be more resistant to chemotherapy, enriched in minimal residual disease cell populations, and responsible for relapse. Here we evaluated clinical and biological associations and the prognostic impact of a high diagnostic CD341/CD382 cell burden in 169 AML patients receiving an allogeneic stem cell transplantation in complete remission. Here, the therapeutic approach is mainly based on immunological graft-versus-leukemia effects. Percentage of bone marrow CD341/CD382 cell burden at diagnosis was measured using flow cytometry and was highly variable (median 0.5%, range 0%-89% of all mononuclear cells). A high CD341/ CD382 cell burden at diagnosis associated with worse genetic risk and secondary AML. Patients with a high CD341/CD382 cell burden had shorter relapse-free and overall survival which may be mediated by residual leukemia-initiating cells in the CD341/CD382 cell population, escaping the graft-versus-leukemia effect after allogeneic transplantation. Evaluating the CD341/CD382 cell burden at diagnosis may help to identify patients at high risk of relapse after allogeneic transplantation. Further studies to understand leukemia-initiating cell biology and develop targeting therapies to improve outcomes of AML patients are needed.
| I N T R O D U C T I O N
Hematopoietic stem cells (HSCs) are found in the bone marrow (BM) and physiologically give rise to all blood cells. 1 The phenotype of HSCs is not well defined, but HSCs have been suggested to be part of the primitive CD341/CD382 cell population. 2 A high amount of the CD341/CD382 cells seem to rest in the G0 cell cycle phase, 3 and are able to initiate retransplantable hematopoiesis in animal models. 4 Acute myeloid leukemia (AML) is a disease originating from the clonal expansion of HSCs or early progenitor cells that have lost the ability to mature. 5 Most researchers agree that similar to the physiological
HSCs, AML-initiating cells-often termed leukemia-initiating cells (LICs)
-also exist within the CD341/CD382 stem cell compartment. [6] [7] [8] [9] LICs -opposed to the majority of circulating, proliferating leukemic blasts or "bulk cells"-are postulated to survive chemotherapy as minimal residual disease (MRD) and cause AML relapse; their nonproliferative state might be one reason for resistance to chemotherapy. [10] [11] [12] [13] [14] When transplanted into NOD/SCID mice, CD341/CD382 cells of AML patients were able to initiate leukemia and growth of tumors histologically similar to the human donor's neoplasm. Hematopoietic stem cell transplantation (HSCT) offers a curative treatment option for AML patients if a suitable donor is available. After achievement of complete remission (CR), HSCT is an established form of consolidation therapy for patients at high risk of relapse. 16 The therapeutic effects of HSCT are mainly based on an immunologic graftversus-leukemia (GvL) reaction. 17 Previous studies have suggested that a high burden of LICs at diagnosis of AML patients treated with chemotherapy increased their relapse probability and associated with inferior outcomes. 14, [18] [19] [20] However, it is at present unknown whether a high burden of LICs has a similar prognostic significance in patients undergoing HSCT. As data support the assumption that LICs are also less immunogenic than the leukemic bulk cells, 21 evaluation of the pretreatment LIC or the CD341/CD382 cell burden in AML patients after allogeneic HSCT might provide important biological and clinical information. The objective of this study was to determine the prognostic significance of the CD341/CD382 cell burden at diagnosis in patients undergoing HSCT and to analyze associations between the CD341/CD382 cell burden and clinical, cytogenetic, and molecular characteristics to provide further biological insights. Figure S1 and Table S2 . 
| P A T I E NT S A ND M E T H O DS

| Definition of clinical end points and statistical analysis
Statistical analyses were performed using the R statistical software platform (version 3.0.2). Utilizing the "OptimalCutpoints" package, an optimal cutoff of 6% was identified that divided the cohort into patients with a high or a low CD341/CD382 cell burden.
Overall survival (OS) was calculated from HSCT until death from any cause and relapse-free survival (RFS) was calculated from HSCT to relapse or death from any cause.
Associations of CD341/CD382 burden with baseline clinical, demographic, and molecular features were compared using the Kruskal-Wallis test and Fisher's exact test for continuous and categorical variables, respectively. For time-to-event analyses, survival estimates were calculated using the Kaplan-Meier method. Groups were compared with the log-rank test. Multivariable analysis is described in Supporting Information.
| R E S U L T S 3.1 | Associations of CD341/CD382 cell burden in BM at diagnosis with genetic and clinical characteristics
The CD341/CD382 cell burden at diagnosis was highly variable (median 0.5%, range 0%-89% of all mononuclear cells). There was no difference in the CD341/CD382 cell burden between younger (<60 years) and older (60 years) patients at diagnosis (P 5 .14, Figure   1A ). However, while there were no differences between age groups in the European LeukemiaNet (ELN), 28 Favorable, Intermediate-I, or
Intermediate-II Genetic Groups ( Figure 1B-D) , older patients in the (26) 36 (29) 3 (14) (continued) ELN Adverse Genetic Group had a trend for a higher CD341/CD382 cell burden at diagnosis than younger patients (P 5 .10, median 2.7% vs 1%, Figure 1E ).
In further analyses, we used a 6% cutoff to divide the patients according to their CD341/CD382 cell burden at diagnosis into low [<6%, n 5 144 (85%)] and high [6%, n 5 25 (15%)] burden groups.
Subgroup analyses restricted to patients receiving HSCT in the first CR are shown in Supporting Information, Table S3 and Figure S5 .
At diagnosis, a high CD341/CD382 cell burden associated with lower platelet counts (P 5 .04), and, by trend, higher white blood cell (WBC) counts (P 5 .07). Patients developing AML as a secondary disease following myelodysplastic syndrome, myeloproliferative neoplasia, or solid tumors were more likely to have a high CD341/CD382 cell burden at diagnosis than patients with de novo AML (P 5 .009).
Patients with a high CD341/CD382 cell burden were more likely to have a complex karyotype (3 cytogenetic abnormalities, 28 P 5 .02), monosomy 5 or deletion of 5q (P 5 .004) or to have a monosomal karyotype 29 (P 5 .004). Among the ELN Genetic Groups, patients with high CD341/CD382 cell burden at diagnosis were less often classified in the Favorable (5% vs 32%) and more often in the Adverse (57% vs 20%) Genetic Group (P 5 .001, Table 1 ). Furthermore, none of the patients with a high CD341/CD382 cell burden at diagnosis harbored a CEBPA mutation (P 5 .13).
| Prognostic value of CD341/CD382 cell burden at diagnosis
A high CD341/CD382 cell burden at diagnosis associated with shorter RFS (P < .001, Figure 2A ) and OS (P 5 .005, Figure 2B ). When the distinct HSCT-conditioning protocols were regarded separately, we Figure 2C ) and OS (P 5 .02, Figure   2D ) for patients with a high CD341/CD382 cell burden treated with NMA-HSCT. In the group of MAC-HSCT-treated patients, only four had a high CD341/CD382 cell burden at diagnosis preventing further subanalyses of the MAC-HSCT-treated patients. Three years after transplantation, 65% of patients with a low diagnostic CD341/CD382 cell burden were alive (including 56% of NMA-HSCT-treated patients) and 60% relapse-free (including 53% of NMA-HSCT-treated patients).
In contrast, in the group with a high CD341/CD382 cell burden, only 43% of patients were alive (including 39% of NMA-HSCT-treated patients) and only 24% (including 24% of NMA-HSCT-treated patients)
remained relapse-free after 3 years. The CD341/CD382 cell burden at diagnosis did also impact on RFS and OS when we restricted our analysis to patients with normal karyotype or de novo AML (Supporting Information, Figures S2 and S3) . Furthermore, in patients with ELN Favorable or Intermediate genetic risk who had a high CD341/CD382
cell burden at diagnosis, we observed a trend for shorter RFS (P 5 .06) and comparable OS (P 5 .11) to patients within the ELN Adverse
Genetic Group (Supporting Information, Figure S8 ).
In multivariable analysis (Table 2) , a high CD341/CD382 cell burden at diagnosis remained significantly associated with shorter RFS (P < .001) and shorter OS (P 5 .04) after adjustment for age at HSCT.
The risk of death or an event was about twice as high in patients with a high diagnostic CD341/CD382 cell burden compared with that of patients with a low CD341/CD382 cell burden. While three previous studies did not find associations of a high CD341/CD382 cell burden with cytogenetics, 18, 19, 34 which may be related to the varying numbers and characteristics of patients analyzed,
| DISCUSSION
we found that patients with a high CD341/CD382 cell burden were more likely to have poor-risk cytogenetics. In line with these findings, we also observed an unequal distribution of patients with high and low CD341/CD382 cell burden in the four ELN Genetic Groups, with patients with a high CD341/CD382 cell burden being least often classified in the Favorable and most frequently in the Adverse Group (Table 1 and Supporting Information, Table S1 ). Another study described an association of a CD341/CD382/ALDH high LIC phenotype cell burden with poor-risk genetics (ELN adverse genetic risk, monosomal, or complex karyotypes) in a cohort of 98 patients. 35 Patients with a high CD341/CD382 cell burden were also more likely to have secondary AML, which was also found for the patients harboring a CD341/CD382/ALDH high LIC phenotype. 35 Thus, the size of the LIC population might be interconnected and contribute to the known adverse outcome of AML with adverse cytogenetic risk, for example, monosomal or complex karyotypes and secondary AML. Furthermore, none of the patients with a high CD341/CD382 cell burden at diagnosis was CEBPA-mutated compared to 17% of patients with a low CD341/CD382 cell burden. We did not observe significant associations of a high CD341/CD382 cell burden with the presence of FLT3-ITD or NPM1 mutations in the entire cohort. However, when we restricted our analysis to patients receiving HSCT in the first CR, none of the patients with a high CD341/CD382 cell burden at diagnosis were NPM1 mutated (P 5 .01, Supporting Information, in more mature AML phenotypes, and that NPM1 mutations occur in more mature CD342 AML cells. 37 As the presence of mutations in both genes impact positively on survival in cytogenetically normal AML, 38 the observed associations may indicate an important biological interaction between CEBPA or NPM1 mutations and the LIC burden at diagnosis in AML patients.
We were able to show that a high CD341/CD382 cell burden at diagnosis associated with shorter RFS and OS after HSCT in CR. In multivariable analysis, the CD341/CD382 cell burden retained its prognostic value, independently of other known prognostic factors.
Some studies demonstrated that a high burden of LICs at AML diagnosis increased the relapse probability after chemotherapy and associated with worse outcomes in different patient cohorts. 13, [18] [19] [20] 35 In general, these studies described a wide range of diagnostic BM CD341/ CD382 cells, from 0.01% up to 71%, in AML patients, similar to the findings in our study. Van Rhenen et al. 14 found the diagnostic CD341/CD382 cell burden of AML patients associated with a higher MRD frequency evaluated by flow cytometry after chemotherapy, shorter OS, RFS, and disease-free survival (DFS). Hwang et al. 34 described a higher CD341/CD382 cell burden at diagnosis in patients who did not achieve a CR after one course of chemotherapy. Khan et al. 20 showed lower CR rates and shorter OS for patients over 60
years of age with a higher diagnostic CD341/CD382 cell burden in blood, but not in BM. Other studies further characterized the analyzed LIC population. Vergez et al. 19 demonstrated that a high CD34 1 CD38 low /2CD1231 cell burden associated with a lower CR rate, shorter DFS, and shorter OS. Wang et al. 18 performed flow cytometry on FISH-preselected blasts in AML with abnormal karyotype and demonstrated a shorter OS and RFS and higher relapse rates in patients with a high FISH1/CD341/CD382 cell burden at diagnosis.
In these studies, the chosen cutoffs to define a high LIC burden were those with the most significant outcome impact and ranged from 1% to 15%. 14, [18] [19] [20] This stands in line with our finding with an optimal Variables considered in the models were those significant at a 5 0.20 in univariable analyses. Variables considered were sex, disease origin (de novo vs secondary), ELN classification, platelet count at diagnosis, blast count in bone marrow at diagnosis, CD341/CD382 burden at diagnosis, age at HSCT, disease status at HSCT (first vs second CR), HLA match (antigen match vs mismatch), and HLA donor type (related vs unrelated).
cutoff at 6% but also significant outcome differences using a 2%, 7.5%, or 10% cutoff (Supporting Information, Figure S4 21 is supported by our finding that HSCT may not be able to fully overcome the described poor prognosis of a high LIC burden at diagnosis. Clinically, not unlike cytotoxic agents, the GvL effect may primarily impact on AML bulk cells, and LICs within their BM niche may at least partly be able to evade the GvL effect. This observation helps to deepen our understanding why after HSCT in CR, some AML patients remain in remission while others do not.
We also compared the CD341/CD382 cell burden in AML patients at diagnosis to the CD341/CD382 BM cell counts during disease course (in CR before HSCT, at day 28 after HSCT, at relapse) and to that of 20 healthy individuals (for details, see Supporting Information). The CD341/CD382 cell counts of AML patients in CR were comparable to or even lower than the CD341/CD382 cell count in the healthy cohort and no significant difference was observed between patients with a high or a low CD341/CD382 cell burden at diagnosis. Given the inferior outcomes of AML patients with a high CD341/ CD382 cell burden at diagnosis that we and others 14, [18] [19] [20] 34, 35 observed, regardless of HSCT as a consolidating therapy, new strategies to target LICs may improve survival. For example, the ability to target the CD341/CD382 cell population was shown for Gemtuzumab ozogamicin, 34 and in vitro combination with tipifarnib suggested synergistic effects, especially on the LIC population. 40 Even though some evidence points to an intraindividual and interindividual heterogenic LIC phenotype, 35 some surface markers such as CD123, 34, 41, 42 CD96, 43 or CD117 44 may be able to discriminate between healthy HSCs and AML LICs, and ways to therapeutically exploit these phenotype differences are under investigation. 45, 46 As CD123 seems to be expressed on LICs rather than HSCs, another promising therapy are Tcells expressing CD123-specific chimeric antigen receptors with high effector activity against AML cell lines and patient samples in vitro without affecting granulocyte or erythroid colonies. 47 Further potential therapeutic targets may be identified from genes and proteins differentially expressed in LICs compared to AML bulk cells or healthy HSCs. 9, [48] [49] [50] Combining therapeutic approaches derived from these studies with chemotherapy and/or HSCT may help to improve outcomes-especially for those patients who have a high diagnostic CD341/CD382 cell burden.
In conclusion, our data demonstrate that the negative prognostic impact of a high CD341/CD382 cell burden at diagnosis seems not to be easily overcome by the GvL effect after HSCT in AML patients. In multivariable analysis, a high CD341/CD382 cell burden at diagnosis was an independent factor for shorter RFS and OS, likely mediated by
LICs within the CD341/CD382 cell population escaping the GvL effects of HSCT. However, HSCT versus non-HSCT studies will be needed to evaluate whether patients with a high CD341/CD382 cell burden at diagnosis might benefit from a HSCT as consolidation therapy, despite their worse outcome than patients with a low burden at diagnosis. Determination of the CD341/CD382 cell burden at AML diagnosis may help to improve risk stratification, adjust disease monitoring and treatment, especially that it is widely available and relatively inexpensive. Finally, novel therapeutic agents targeting AML LICs within the CD341/CD382 cell population may help to improve outcomes of these patients.
